SCM
RIGL icon

Stonepine Capital Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Stonepine Capital Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-309,100
Closed -$5M – 54
2024
Q3 		$5M Buy
309,100
+4,100
+1% +$48.2K 3.16% 7
2024
Q2 		$2.51M Buy
305,000
+200,976
+193% +$2.1M 2.29% 9
2024
Q1 		$1.54M Buy
+104,024
New +$1.4M 1.22% 13
2020
Q2 		– Sell
-1,000
Closed -$16K – 18
2020
Q1 		$16K Buy
+1,000
New +$21.3K 0.02% 27
2018
Q3 		– Sell
-149,659
Closed -$4.24M – 34
2018
Q2 		$4.24M Buy
+149,659
New +$5.33M 2.57% 14

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Stonepine Capital Management's RIGL Position: Q4 2024 in Review

Stonepine Capital Management sold out of Rigel Pharmaceuticals (RIGL) in Q4 2024, closing a stake of 309,100 shares — an estimated $5M sold.

Stonepine Capital Management first reported a position in RIGL in Q2 2018 and held it in 5 quarters. The position peaked at $5M in Q3 2024. 122 funds tracked by Wall St. Rank hold RIGL as of Q4 2024.

  • Stonepine Capital Management reported no remaining Rigel Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Stonepine Capital Management sold 309,100 Rigel Pharmaceuticals shares in Q4 2024, an estimated $5M.
  • Stonepine Capital Management first reported a position in Rigel Pharmaceuticals in Q2 2018 and held it in 5 quarters.
  • Stonepine Capital Management's Rigel Pharmaceuticals position peaked at $5M in Q3 2024.
  • 122 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2024.

Based on Stonepine Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.